Abstract
1. Monotherapy with mitotane is recommended in patients after incomplete surgical resection or in patients not fit for surgery or chemotherapy 1 ⊕⊕OO. 2. Monotherapy with mitotane may be recommended in advanced ACC with involvement of few organs and low-grade mitotic index, particularly when RFS after removal of the primary tumor has been longer than 12 months 1 ⊕OOOO. 3. The chemotherapeutic regimen EDP in combination with mitotane is recommended in most patients with advanced or metastatic ACC 1 ⊕⊕⊕⊕. 4. There are insufficient data to recommend a particular targeted therapy in patients with advanced ACC beyond ongoing clinical trials.
Lingua originale | English |
---|---|
pagine (da-a) | 103-121 |
Numero di pagine | 19 |
Rivista | Journal of Endocrinological Investigation |
Volume | 39 |
DOI | |
Stato di pubblicazione | Pubblicato - 2016 |
Keywords
- Adjuvant treatment
- Adrenal Cortex Neoplasms
- Adrenocortical Carcinoma
- Adrenocortical carcinoma
- Biopsy, Fine-Needle
- Consensus
- Diagnostic Imaging
- Diagnostic Techniques, Endocrine
- Hormones
- Humans
- Italy
- Magnetic Resonance Imaging
- Mitotane
- Overall survival
- Positron-Emission Tomography
- Prognostic factors
- Recurrence-free survival
- Tomography, X-Ray Computed